Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amylyx Pharmaceuticals Inc ( (AMLX) ) just unveiled an announcement.
On March 24, 2026, Amylyx Pharmaceuticals updated its corporate presentation to reflect several clinical development milestones across its rare disease pipeline. The company reported completion of enrollment in the Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, highlighted new exploratory analyses from the Phase 2 PREVENT study, and confirmed that enrollment in Cohort 2 of the Phase 1 LUMINA trial of AMX0114 for ALS was completed in March 2026.
The updated materials underscore Amylyx’s progress toward potentially bringing the first-in-class GLP-1 receptor antagonist avexitide to market for post-bariatric hypoglycemia, an orphan condition with an estimated 160,000 prevalent patients. Demonstrated Phase 2 efficacy in reducing hypoglycemic events, combined with regulatory designations such as Breakthrough Therapy and Orphan Drug status, reinforces the company’s positioning in high unmet-need endocrine and neurodegenerative indications and may have meaningful implications for patients, clinicians and investors as key readouts approach.
The most recent analyst rating on (AMLX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.
Spark’s Take on AMLX Stock
According to Spark, TipRanks’ AI Analyst, AMLX is a Neutral.
The score is held down primarily by deteriorated financial performance (revenue dropping to zero and continued losses/cash burn), partially offset by strong technical momentum and a constructive earnings call centered on clear Phase III timelines and an expected cash runway into 2028.
To see Spark’s full report on AMLX stock, click here.
More about Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc. is a biotechnology company focused on developing novel therapies for diseases with high unmet medical needs, particularly serious and fatal endocrine conditions and neurodegenerative diseases. Its pipeline includes avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis, and AMX0318 for post-bariatric hypoglycemia and other rare diseases.
Average Trading Volume: 1,303,465
Technical Sentiment Signal: Buy
Current Market Cap: $1.5B
Learn more about AMLX stock on TipRanks’ Stock Analysis page.